Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 401 clinical trials
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam in Epilepsy

The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in participants with focal onset seizures who are receiving levetiracetam and up to 3 other anti-epileptic drugs (AEDs) (double-blind …

  • 7 views
  • 02 Jun, 2022
  • 26 locations
TMS for Symptom Reduction in Schizophrenia

investigators predict that such modulation will correct abnormal activities in patients with schizophrenia, reduce symptoms, especially auditory hallucination, and improve working memory/sustained attention

  • 3 views
  • 24 Feb, 2022
  • 1 location
Improving Cognition Via Exercise in Schizophrenia

People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability. Also, people with schizophrenia are

  • 12 views
  • 20 Jun, 2022
  • 4 locations
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the

  • 3 views
  • 14 Nov, 2021
  • 1 location
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

Schizophrenia (SZ) is a highly debilitating neuropsychiatric disorder of young adulthood onset and a leading cause of disability worldwide. While treatments delivered at early stages of the

Accepts healthy volunteers
  • 7 views
  • 03 Mar, 2022
Efficacy and Mechanisms of Low-intensity Focused Ultrasound on Negative Symptoms in Patients With Schizophrenia

Based on our research background, we hypothesize that LIFUS has neuromodulation effects on brain cortex and the active LIFUS on left-DLPFC would improve negative symptoms in schizophrenia

  • 0 views
  • 29 Aug, 2021
  • 1 location
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

This study will test whether CVL-562 (PF-06412562), a dopamine 1 partial agonist novel compound, affects working memory neural circuits in patients with early episode schizophrenia. The overall

  • 24 views
  • 24 Jul, 2021
  • 4 locations
Deep Transcranial Magnetic Stimulation for the Treatment of Treatment Resistance Schizophrenia

-related functional network in patients with treatment resistance schizophrenia,this research plan to utilise multimodal functional magnetic imaging method(including structural MRI,resting-state functional

  • 0 views
  • 23 Sep, 2021
  • 1 location
Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms (FRS) on Schizophrenia (Schirang)

First rank symptoms are core symptoms of schizophrenia. the investigators want to offer an integrative approach to better understanding of the mechanisms involved in the first rank symptoms and

  • 12 views
  • 12 May, 2022
  • 1 location
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

refractory schizophrenia. Part 1 Objectives: There are two primary objectives for Part 1 of this study: To evaluate, in terms of dose-response, the effectiveness of NaBen (1000 and 2000

  • 55 views
  • 24 Feb, 2022
  • 1 location